Cognition Therapeutics, Inc.

NASDAQ: CGTX · Healthcare · Biotechnology

PublicHQ Purchase, NYCIK 0001455365Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 45DQ —GM —SS 40

v0.1 · 35/100 weight · pillars only

↑ filing timeliness, balance-sheet leverage · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$23.5M

Employees

Market cap

$86.1M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$23.5M-$23.5M2025

Operating income-$47.8M-$47.8M2025

Total assets$48.4M$48.4M2025

Liabilities$14.1M$14.1M2025

Equity$34.3M$34.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Cognition Therapeutics, Inc. earned -$23.5M in FY2025 net income.

Peers · Healthcare

Cardiff Oncology, Inc.53D Microbot Medical Inc.47D NeurAxis, Inc.45D Outset Medical, Inc.52D

Key facts

CEOLisa Ricciardi

SectorHealthcare

IndustryBiotechnology

HeadquartersPurchase, NY

ExchangeNASDAQ: CGTX

Employees25

IPO date2021-10-08

Latest filings

8-K2026-06-24 8-K2026-06-18 8-K2026-06-04 8-K2026-05-21 10-Q2026-05-08 8-K2026-05-07 DEF 14A2026-04-27 10-K2026-03-26

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.